[HTML][HTML] Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations
WG Wierda, A Rawstron, F Cymbalista, X Badoux… - Leukemia, 2021 - nature.com
Assessment of measurable residual disease (often referred to as “minimal residual disease”)
has emerged as a highly sensitive indicator of disease burden during and at the end of …
has emerged as a highly sensitive indicator of disease burden during and at the end of …
Bone marrow transplantation for Behçet's disease: a case report and systematic review of the literature
T Soysal, A Salihoğlu, SN Esatoğlu, E Gültürk… - …, 2014 - academic.oup.com
Objectives. Behçet's disease (BD) can be life threatening and may be refractory to
corticosteroids and immunosuppressives. There has been some experience with …
corticosteroids and immunosuppressives. There has been some experience with …
[PDF][PDF] A reappraisal of the association between Behçet's disease, myelodysplastic syndrome and the presence of trisomy 8: a systematic literature review
SN Esatoglu, G Hatemi, A Salihoglu… - Clin Exp …, 2015 - clinexprheumatol.org
Objective. A number of patients with Behçet's disease (BD) associated with myelodysplastic
syndrome (MDS) with or without trisomy 8 have been reported. A high frequency of …
syndrome (MDS) with or without trisomy 8 have been reported. A high frequency of …
The frequency of tuberculosis in adult allogeneic stem cell transplant recipients in Turkey
T Budak-Alpdogan, Y Tangün… - Biology of Blood and …, 2000 - Elsevier
In general, tuberculosis (Tb) is rarely seen in allogeneic stem cell transplant (alloSCT)
recipients, but this observation has been challenged in developing countries such as …
recipients, but this observation has been challenged in developing countries such as …
Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data …
Objectives: Newer tyrosine kinase inhibitors (TKIs)(bosutinib, ponatinib) and allogeneic
hematopoietic stem cell transplantation (allo-HSCT) can be utilized as a salvage therapy in …
hematopoietic stem cell transplantation (allo-HSCT) can be utilized as a salvage therapy in …
T-cell-rich B-cell lymphoma: a clinicopathologic study of 21 cases and comparison with 43 cases of diffuse large B-cell lymphoma
Clinicopathologic features of 21 patients with T-cell-rich B-cell lymphoma (TCRBCL) were
reviewed and compared to 43 patients with diffuse large B-cell lymphoma (DLBCL) to …
reviewed and compared to 43 patients with diffuse large B-cell lymphoma (DLBCL) to …
17p Deletion is associated with resistance of B-cell chronic lymphocytic leukemia cells to in vitro fludarabine-induced apoptosis
We explored the relationship between the cytogenetic/biologic characteristics of B-chronic
lymphocytic leukemia (B-CLL) cells and their tendency to undergo spontaneous or …
lymphocytic leukemia (B-CLL) cells and their tendency to undergo spontaneous or …
Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without …
Dasatinib is a potent second generation TKI, and it is widely used in patients with CML, both
in the up-front setting and failure after imatinib. Lymphocytosis in cases receiving dasatinib …
in the up-front setting and failure after imatinib. Lymphocytosis in cases receiving dasatinib …
[HTML][HTML] Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy
Ahmet Emre Eskazan, Teoman Soysal, Seniz Ongoren, Emine Gulturk, Burhan Ferhanoglu,
and Yildiz Aydin Istanbul University Cerrahpasa Faculty of Medicine, Department of Internal …
and Yildiz Aydin Istanbul University Cerrahpasa Faculty of Medicine, Department of Internal …
Outcomes of chronic myeloid leukemia patients with early molecular response at 3 and 6 months: a comparative analysis of generic imatinib and glivec
AE Eskazan, S Sadri, D Keskin, M Ayer… - … Myeloma and Leukemia, 2017 - Elsevier
Background The molecular response at 3 months of the original imatinib (OI) in patients with
chronic myeloid leukemia has prognostic significance; however, this has never been tested …
chronic myeloid leukemia has prognostic significance; however, this has never been tested …